Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,4-Diallyloxybenzene SCHEMBL302448 | 0.84 | CA12 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL826483 | 0.83 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3768879 | 0.81 | KDM4E (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7929785 | 0.81 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7782792 | 0.81 | ALDH1A1 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20054071 | 0.79 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5098606 | 0.79 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7929787 | 0.79 | ALDH1A1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4512907 | 0.79 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2521425 | 0.79 | CA12 (0.50) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635568-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA Pharmaceuticals Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-3672954-B1 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-117466803-A | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-111132976-B | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20220298151-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200270239-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2020-08-27 | — | — | US | disclosed |
| EP-3672954-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | Acadia Pharmaceuticals Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-0819000-B1 | NODULISPORIC ACID DERIVATIVES | MERCK & CO INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-7524977-B2 | Process for producing fluoroalkanesulfonamide derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7524977-B2 | Process for producing fluoroalkanesulfonamide derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20080058538-A1 | Process for producing fluoroalkanesulfonamide derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2008-03-06 | — | — | US | disclosed |
| US-20080058538-A1 | Process for producing fluoroalkanesulfonamide derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2008-03-06 | — | — | US | disclosed |
| EP-0819000-A4 | NODULISPORIC ACID DERIVATIVES | MERCK & CO INC (US) | 2001-04-11 | — | — | EP | disclosed |
| US-5962499-A | ACARICIDAL, ANTIPARASITIC, INSECTICIDAL AND ANTHELMINTIC AGENTS | MERCK & CO., INC. (US) | 1999-10-05 | — | — | US | disclosed |
| CN-1184423-A | Nodulisporic acid derivatives | MERCK & CO INC (US) | 1998-06-10 | — | — | CN | disclosed |
| EP-0819000-A1 | NODULISPORIC ACID DERIVATIVES | Merck & Co., Inc. (US) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996029073-A1 | NODULISPORIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270239-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | CA12 604/4885CA1 1591/4885CA2 1024/4885 |
| US-20220298151-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | CA12 604/4885CA1 1591/4885CA2 1024/4885 |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | CA12 604/4885CA1 1591/4885CA2 1024/4885 |
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | CA12 604/4885CA1 1591/4885CA2 1024/4885 |
| US-20080058538-A1 | Process for producing fluoroalkanesulfonamide derivatives | AFF1, AFF2, RER1 | CA12 418/4885CA1 372/4885CA2 81/4885 |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | CA12 604/4885CA1 1591/4885CA2 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.